Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is growing into an epidemic affecting 1 in 4 adults. There is a need
for research to elucidate the prevalence of ischemic cardiomyopathy in patients diagnosed
with AF. The objective of this study is to demonstrate the utility of MRI in assessment of
coronary artery disease. The specific objective is to demonstrate sensitivity/specificity
comparable to that reported in meta-analyses of non-AF patients and adenosine (90% /80%) in
an AF population using the time-efficient vasodilator regadenoson that requires only a single
intravenous (IV).